{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-032142","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2026-08-11T12:30:33+00:00","discovered_at":"2026-08-11T12:35:02.310845+00:00","generated_at":"2026-08-11T12:35:27.103193+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PDS Biotech refocuses on PDS0301 in mCRC; discontinues PDS0101 Phase 3 trial","bullets":["PDS0301 showed 71% ORR at 6 months and 80% 24-month survival in MSS/pMMR mCRC with liver metastases.","Company discontinues PDS0101 Phase 3 VERSATILE-003 trial and will pursue strategic partnerships for PDS0101.","PDS0301 has been studied in >380 patients with encouraging safety; Phase 2b trial designed with FDA feedback.","PDS0301 also evaluated in prostate, Kaposi sarcoma, HPV16+ cancers via NCI-sponsored trials.","Q2 2026 financial results scheduled for announcement on August 13, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-032142","json":"https://secwatch.observer/filing/0001140361-26-032142.json","markdown":"https://secwatch.observer/filing/0001140361-26-032142.md","text":"https://secwatch.observer/filing/0001140361-26-032142.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126032142/0001140361-26-032142-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126032142/ef20079931_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-11T12:35:27.103193+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}